Episode Details

Novo Nordisk is suing Eli Lilly over alleged false advertising, claiming Lilly’s claims about Mounjaro and Zepbound unfairly tout superior weight loss and A1c control compared to Ozempic and Wegovy—by cherry-picking data and using lower doses of Novo’s drugs. Lilly fires back, insisting their ads are truthful and backed by head-to-head trial data, while Novo argues the studies are outdated and lack direct comparisons using the most effective doses. As the GLP-1 drug race heats up, this legal clash underscores the fierce competition—and unanswered questions—surrounding these blockbuster medications.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/1a262a4ce22dedb7